Private ADHD and autism assessment ads are normalising diagnosis as a consumer product
A billboard outside a supermarket tells parents to “skip the waiting lists.” A discount code offers £100 off an ADHD or autism assessment for a child, or £150 off if both assessments are booked together. On a bus, another advert suggests that distractibility and stress could signal undetected ADHD and points people toward a Right to Choose provider.
The messaging is blunt, commercially polished, and deliberately urgent. It treats diagnostic assessment less like a careful clinical process and more like a retail offer, complete with price cuts and time-limited appeal. In a system already strained by long waits, that framing has obvious power. Families searching for answers are being asked to see diagnosis not as a complex medical and developmental judgment, but as something to be obtained efficiently, and perhaps purchased with a discount code.
A ban on advertising would not be enough
A recently published Fonagy review into mental health conditions, ADHD, and autism recommended that direct-to-public advertising of NHS-funded autism and ADHD assessment services should be banned. The argument for that step is straightforward: public advertising can intensify demand, blur the line between clinical need and commercial persuasion, and encourage people to seek assessments on the basis of generic distress rather than a structured evaluation of symptoms and impairment.
But the commentary argues that an advertising ban alone would leave the core problem untouched. The issue is not just how providers attract patients. It is also how modern diagnosis has become entangled with expanding definitions, cultural expectations, and a broadening sense that many forms of stress, distraction, or difficulty in daily life may be explained by ADHD or autism.
The concern reaches beyond marketing tactics. It speaks to the way diagnostic categories travel through society. When a condition becomes increasingly visible in public discourse, more people begin to map their experiences onto it. Some will be correctly identified after years of missed need. Others may be drawn into assessment pathways by language that is too broad, too persuasive, or too commercially motivated to support careful clinical triage.
That tension sits at the center of the current debate.
Waiting lists create fertile ground for commercial pressure
Long waiting lists make the market for private assessment especially vulnerable to exploitation. When access through ordinary routes is slow or uncertain, any service promising speed gains immediate appeal. The commercial logic is obvious: delayed public access creates a vacuum, and private providers can step into that space with advertisements that promise convenience, certainty, and relief.
In that setting, ADHD and autism assessments can acquire the feel of consumer services. Families are nudged toward urgency before any clinician has established whether the child’s difficulties fit a diagnosis, whether other explanations are more likely, or whether the most useful intervention might lie elsewhere. Diagnostic inflation is not only a matter of too many labels. It can also shift attention away from the broader social and educational factors that shape behavior, attention, distress, and development.
For clinicians, the risk is twofold. A child who genuinely needs assessment may arrive with expectations already shaped by advertising. Another child may be referred after being persuaded that common difficulties are evidence of a disorder. Both pathways complicate the task of separating impairment from normal variation, and clinical judgment from marketing pressure.
Expansion of diagnosis is being driven by more than access alone
The article’s central warning is that stricter regulation is necessary, but insufficient. The “Wild West” of assessment practice cannot be fixed without addressing the conceptual and cultural forces that have helped drive demand upward.
That argument matters because it shifts the debate from regulation alone to the social meaning of diagnosis. The expansion of ADHD and autism assessment is not happening in a vacuum. Public awareness has grown, professional language has widened, and digital platforms have made diagnostic narratives far more visible than they once were. In that environment, the boundary between recognition and overinterpretation becomes harder to police.
A diagnostic label can be validating, especially for people who have been overlooked. It can open the door to accommodations, support, and a clearer understanding of lifelong struggles. But when the route to diagnosis is shaped by commercial incentives, the promise of recognition can be mixed with a less visible pressure to convert uncertainty into a billable assessment.
The supermarket billboard captures that tension in miniature. A clinical service marketed like a consumer deal turns a serious developmental and psychiatric evaluation into a product with a promotional hook. The bus advert does something similar, using everyday distress as a starting point for a diagnostic pitch.
That is where the deeper concern lies: not simply that providers profit, but that the language of profit begins to influence how symptoms are interpreted in the first place.
Regulation, triage, and diagnostic restraint
Any serious response has to start with tighter rules on direct-to-public advertising. Claims that imply hidden disorder in ordinary behavior should face far closer scrutiny, particularly when the service being promoted is connected to NHS-funded pathways. Marketing should not be allowed to manufacture clinical urgency where careful assessment is still needed.
Yet the article makes clear that regulation cannot do all the work. If rising demand is being propelled by broader social assumptions about neurodevelopmental difference, then policy alone will not restore balance. Clinicians, commissioners, educators, and policymakers will need to confront how diagnostic categories are being used, understood, and sold.
The practical consequence is hard to avoid: when assessment becomes a market, diagnosis is pulled in two directions at once. One pull is toward access for those who have been missed. The other is toward expansion, speed, and consumer-style uptake. Health systems will struggle to manage both without clearer boundaries around advertising, referral, and diagnostic threshold.
The commentary leaves no room for complacency. The current model rewards visibility, volume, and speed. Clinical caution is much harder to advertise.